Advertisement
ARRY vs SEER
Which Stock Would AI Choose? Array Technologies (ARRY) vs. Seer, Inc. (SEER) Stock Comparison
Key Takeaways
- ARRY is a solar tracking systems manufacturer with a record orderbook but sharply negative recent price momentum, while SEER is an early-stage proteomics (large-scale protein analysis) company trading near its 52-week low.
- Both stocks are unprofitable on a net-income basis, but their profiles diverge sharply: ARRY generates roughly $1.2 billion in trailing revenue versus SEER's approximate $14 million.
- ARRY carries a broad "Buy" analyst consensus and triple-digit average upside to price targets, whereas SEER faces an activist takeover campaign and a CFO transition.
- SEER's roughly $220 million cash position provides a substantial runway relative to its small market capitalization, a key stability factor ARRY lacks at similar scale.
- Risk profiles differ by sector: ARRY is exposed to utility-scale solar demand and policy, while SEER is exposed to academic funding cycles and competitive pressure in life-sciences tools.
- For more context on each name, explore ARRY Major News and ARRY Today's Price Move, as well as SEER Major News and SEER Today's Price Move.
- To see how AI-powered systems are currently positioning across the market, visit the Trending AI Robots page.
Introduction
Array Technologies and Seer, Inc. occupy opposite corners of the market, yet both illustrate how sharply sentiment can diverge from fundamentals. ARRY is a scaled supplier of solar tracking equipment to utility-scale developers, while SEER is a pre-profit life-sciences company commercializing proteomics instruments. This stock comparison may appeal to traders evaluating relative momentum, as well as investors weighing a cyclical industrials turnaround against a cash-rich but early-stage science platform. Because the two companies face different demand drivers and risk factors, a head-to-head view helps clarify how each might behave in the current market environment.
ARRY Overview and Recent Performance
Array Technologies manufactures single- and dual-axis solar trackers and related software that orient panels toward the sun, serving utility and distributed-generation projects globally. In recent weeks, the stock has traded in the low single digits, reflecting a decline of roughly 64% year-to-date and a 52-week range well above current levels. This price weakness contrasts with operational milestones: management reported a record orderbook of approximately $2.5 billion and a book-to-bill ratio (orders booked relative to revenue billed) of around 2x in recent quarters, indicating solid demand visibility.
Sentiment has been shaped by conflicting signals. Analysts at firms including Mizuho upgraded the stock to Outperform, citing an attractive risk/reward and expectations for a 2027 recovery, while others lowered price targets on concerns about a demand slowdown and cash needs. Recent quarters have shown strong adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) beats, yet revenue guidance has at times missed estimates, keeping the market cautious. With a forward price-to-earnings ratio near 4.4 and a consensus "Buy" rating, ARRY presents a valuation-versus-momentum tension.
SEER Overview and Recent Performance
Seer, Inc. develops the Proteograph Product Suite, an integrated platform for deep, unbiased proteomics used by researchers and biobanks to study proteins at scale. SEER trades near $2, close to its 52-week low, with a market capitalization of roughly $108 million. The company holds approximately $220 million in cash and investments, meaning its cash position exceeds its market value, an unusual stability buffer for a pre-profit company.
Recent activity has been marked by both scientific and governance developments. Seer surpassed 100 peer-reviewed customer publications and advanced population-scale studies such as PRECISE-SG100K, while announcing the departure of its CFO. At the same time, activist shareholders have submitted a non-binding acquisition proposal at $2.40 per share and launched a proxy campaign, introducing event-driven uncertainty. Revenue remains small and has declined year-over-year amid a soft academic funding environment and competitive pressure, though full-year guidance has been reaffirmed.
Trending AI Robots
Tickeron maintains a large library of AI-powered trading bots spanning thousands of tickers and a wide range of strategies, timeframes, and risk profiles. Rather than showcasing every bot, the platform curates a dedicated Trending AI Robots section that highlights only those systems best suited to prevailing market conditions. These bots differ in trading style, performance statistics, and the specific set of tickers they trade, allowing users to evaluate options that align with their own approach. For investors tracking names such as ARRY and SEER, reviewing currently trending systems can offer a data-driven view of how automated strategies are positioning. Explore the Trending AI Robots page to see which bots are drawing attention now.
Head-to-Head Comparison
The most fundamental contrast is scale and stage. ARRY is an established industrial manufacturer with meaningful revenue, a large orderbook, and a clear path to profitability, but its stock has been under heavy selling pressure tied to demand-cycle fears. SEER is a small-cap innovator whose revenue base is minimal and declining, yet whose cash balance and takeover interest provide downside support and potential catalysts.
Growth drivers also diverge. ARRY leans on utility-scale solar deployment, domestic manufacturing credits, and international expansion, making it sensitive to energy policy and financing conditions. SEER depends on adoption of a still-nascent technology by academic, biopharma, and biobank customers, making it sensitive to research funding and competition. On momentum, both names have lagged, but ARRY has a broader analyst endorsement while SEER carries event risk from its activist campaign and leadership changes. These trade-offs make the two suitable for very different investor profiles.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward ARRY in the current environment. The company shows a record orderbook, a favorable analyst consensus, and a depressed valuation relative to projected earnings, suggesting that negative sentiment may already be substantially reflected in the price. In contrast, SEER combines strong cash stability with lower earnings visibility, ongoing revenue declines, and governance-related uncertainty, which tends to reduce trend consistency. This is a probabilistic assessment of relative positioning rather than a definitive prediction, and both stocks carry distinct risks that could shift the balance as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARRY is a Hold and SEER is a Hold.
ARRY's RSI Indicator remains in overbought zone for 3 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
ARRY broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ARRY as a result. In 75 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for ARRY just turned positive on October 27, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
ARRY moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARRY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Following a +40.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 191 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.462) is normal, around the industry mean (2.537). P/E Ratio (-6.099) is within average values for comparable stocks, (6.086). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ARRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Momentum Indicator for SEER turns negative, indicating new downward trend
SEER saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 72 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SEER turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
SEER moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SEER crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for SEER entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEER advanced for three days, in 162 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
SEER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (3.498). P/E Ratio (-1.336) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.800) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. SEER’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ARRY | SEER | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 39 | 77 | |
P/E GROWTH RATING 1..100 | 43 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRY's Valuation (8) in the Biotechnology industry is in the same range as SEER (34) in the null industry. This means that ARRY’s stock grew similarly to SEER’s over the last 12 months.
ARRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SEER (100) in the null industry. This means that ARRY’s stock grew similarly to SEER’s over the last 12 months.
SEER's SMR Rating (96) in the null industry is in the same range as ARRY (100) in the Biotechnology industry. This means that SEER’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for SEER (77) in the null industry. This means that ARRY’s stock grew somewhat faster than SEER’s over the last 12 months.
SEER's P/E Growth Rating (22) in the null industry is in the same range as ARRY (43) in the Biotechnology industry. This means that SEER’s stock grew similarly to ARRY’s over the last 12 months.
| ARRY | SEER | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 4 days ago 69% |
| Stochastic ODDS (%) | 4 days ago 90% | 4 days ago 73% |
| Momentum ODDS (%) | 4 days ago 85% | 4 days ago 89% |
| MACD ODDS (%) | 4 days ago 83% | 4 days ago 86% |
| TrendWeek ODDS (%) | 4 days ago 79% | 4 days ago 84% |
| TrendMonth ODDS (%) | 4 days ago 80% | 4 days ago 83% |
| Advances ODDS (%) | 6 days ago 76% | 13 days ago 72% |
| Declines ODDS (%) | 15 days ago 89% | 5 days ago 84% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 76% |
| Aroon ODDS (%) | 4 days ago 81% | 4 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRY’s FA Score shows that 1 FA rating(s) are green while SEER’s FA Score has 1 green FA rating(s).
- ARRY’s FA Score: 1 green, 4 red.
- SEER’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 5 TA indicator(s) are bullish while SEER’s TA Score has 4 bullish TA indicator(s).
- ARRY’s TA Score: 5 bullish, 5 bearish.
- SEER’s TA Score: 4 bullish, 6 bearish.
Price Growth
ARRY (@Alternative Power Generation) experienced а +72.71% price change this week, while SEER (@Biotechnology) price change was -2.98% for the same time period.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was +6.20%. For the same industry, the average monthly price growth was -3.67%, and the average quarterly price growth was -41.36%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
ARRY is expected to report earnings on Mar 03, 2027.
SEER is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Alternative Power Generation (+6.20% weekly)The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARRY and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARRY has been closely correlated with NXT. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARRY jumps, then NXT could also see price increases.
| Ticker / NAME | Correlation To ARRY | 1D Price Change % | ||
|---|---|---|---|---|
| ARRY | 100% | +10.47% | ||
| NXT - ARRY | 67% Closely correlated | +5.35% | ||
| SHLS - ARRY | 61% Loosely correlated | +12.06% | ||
| AXON - ARRY | 53% Loosely correlated | -18.18% | ||
| INO - ARRY | 52% Loosely correlated | -16.21% | ||
| ENPH - ARRY | 50% Loosely correlated | -1.74% | ||
More | ||||
SEER and
Correlation & Price change
A.I.dvisor indicates that over the last year, SEER has been loosely correlated with AXON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SEER jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To SEER | 1D Price Change % | ||
|---|---|---|---|---|
| SEER | 100% | N/A | ||
| AXON - SEER | 56% Loosely correlated | -18.18% | ||
| ARRY - SEER | 47% Loosely correlated | +10.47% | ||
| RNA - SEER | 36% Loosely correlated | +0.24% | ||
| VCYT - SEER | 35% Loosely correlated | +0.67% | ||
| DNA - SEER | 34% Loosely correlated | +13.35% | ||
More | ||||